Literature DB >> 18594872

Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients.

Sabine Irtan1, Said Azougagh, Caroline Monchaud, Michel Popon, Véronique Baudouin, Evelyne Jacqz-Aigrain.   

Abstract

Therapeutic drug monitoring (TDM) of mycophenolate mofetil (MMF) is recommended to guide immunosuppression. High-performance liquid chromatography with ultraviolet (HPLC-UV) or the enzyme-multiplied immunoassay technique (EMIT), used to measure mycophenolic acid (MPA) were compared in an exclusive paediatric renal transplant population. Twenty patients were included as part of the pharmacokinetics study of MMF, and 88 additional samples were drawn for TDM. Agreement between HPLC-UV and EMIT was assessed by the Bland-Altman method. With the two methods, pre-dose concentrations were not normally distributed. After logarithmic transformation, their mean was 0.79 +/- 1.16 microg ml(-1) and their mean difference was 0.34 +/- 0.16 microg ml(-1) [95% confidence interval (95%CI 0.30-0.38 microg ml(-1), with antilogarithmic values of these limits of 1.34-1.46 microg ml(-1)). Area under the curve (AUC)(HPLC) and AUC(EMIT) were normally distributed. Their mean was 52.42 +/- 25.91 mg x h/l and their mean difference was 15.22 +/- 8 mg x h/l (95%CI 11.99-18.45 mg x h/l), the Bland-Altman plot showing a bias proportional to the mean. Our data showed the absence of agreement between the HPLC and EMIT methods, with an average positive bias of 15% with the EMIT. Further studies are required to determine which method is best appropriate for TDM of MMF in children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594872     DOI: 10.1007/s00467-008-0877-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  35 in total

1.  The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes.

Authors:  M Shipkova; E Wieland; E Schütz; C Wiese; P D Niedmann; M Oellerich; V W Armstrong
Journal:  Transplant Proc       Date:  2001 Feb-Mar       Impact factor: 1.066

Review 2.  Therapeutic drug monitoring of mycophenolate mofetil in transplantation.

Authors:  Teun van Gelder; Yann Le Meur; Leslie M Shaw; Michael Oellerich; David DeNofrio; Curtis Holt; David W Holt; Bruce Kaplan; Dirk Kuypers; Bruno Meiser; Burkhard Toenshoff; Richard D Mamelok
Journal:  Ther Drug Monit       Date:  2006-04       Impact factor: 3.681

3.  Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children.

Authors:  E Jacqz-Aigrain; E Khan Shaghaghi; V Baudouin; M Popon; D Zhang; A Maisin; C Loirat
Journal:  Pediatr Nephrol       Date:  2000-02       Impact factor: 3.714

4.  Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation.

Authors:  Christine E Staatz; Stephen B Duffull; Bryce Kiberd; Albert D Fraser; Susan E Tett
Journal:  Eur J Clin Pharmacol       Date:  2005-07-28       Impact factor: 2.953

5.  Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients.

Authors:  L Ghio; M Ferraresso; S M Viganò; F Ginevri; F Perfumo; B Gianoglio; L Murer; G Zacchello; L Dello Strologo; M Cardillo; S Tirelli; U Valente; A Edefonti
Journal:  Transplant Proc       Date:  2005-03       Impact factor: 1.066

6.  Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.

Authors: 
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

7.  Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.

Authors:  G Filler; J Foster; R Berard; I Mai; N Lepage
Journal:  Transplant Proc       Date:  2004-06       Impact factor: 1.066

8.  Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients.

Authors:  Chantal Le Guellec; Hélène Bourgoin; Matthias Büchler; Yann Le Meur; Yvon Lebranchu; Pierre Marquet; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of mycophenolate mofetil.

Authors:  R E Bullingham; A J Nicholls; B R Kamm
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

10.  Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy.

Authors:  Guido Filler
Journal:  Transpl Int       Date:  2004-01-29       Impact factor: 3.782

View more
  4 in total

Review 1.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

2.  Positive bias in mycophenolic acid concentrations determined by the CEDIA assay compared to HPLC-UV method: is CEDIA assay suitable for therapeutic drug monitoring of mycophenolic acid?

Authors:  Amitava Dasgupta; Myrtle Johnson
Journal:  J Clin Lab Anal       Date:  2013-01       Impact factor: 2.352

Review 3.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

4.  Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium.

Authors:  Yichen Jia; Bo Peng; Long Li; Jina Wang; Xuanchuan Wang; Guisheng Qi; Ruiming Rong; Liming Wang; Jianxin Qiu; Ming Xu; Tongyu Zhu
Journal:  Ther Drug Monit       Date:  2017-02       Impact factor: 3.681

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.